Goldman Sachs released a research report stating that it reaffirms that after 3 years of weak growth, this year's profit will improve the 2023-2026 compound annual growth rate forecast of 13% and the compound annual growth rate of 4.4% from 2020 to 2023; the worst situation of the drug NBP (NBP) launched since 2022 will be a growth engine is fully reflected in the stock price. The current valuation does not fully reflect the potential of overseas and new technology platforms. The target price was raised from HK$9.73 to HK$10.26.
高盛发布研究报告称重申石药集团(01093.HK)“买入”评级认为经过3年的增长乏力后今年盈利将改善2023至2026年复合年均增长率预测为13%而2020至2023年复合年均增长率为4.4%;2022年以来推出的产品将成为增长动力旗下药物恩必普(NBP)最坏的情况已充分反映在股价。目前估值尚未充分反映海外和新技术平台潜力目标价从9.73港元上调至10.26港元。
Goldman Sachs released a research report stating that it reaffirms that after 3 years of weak growth, this year's profit will improve the 2023-2026 compound annual growth rate forecast of 13% and the compound annual growth rate of 4.4% from 2020 to 2023;
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.